Madrigal Pharmaceuticals, Inc. MDGL
We take great care to ensure that the data presented and summarized in this overview for MADRIGAL PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDGL
View all-
Janus Henderson Group PLC London, X02.6MShares$572 Million0.39% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$433 Million6.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.94MShares$428 Million6.26% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.78MShares$391 Million34.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.67MShares$367 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.21MShares$266 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD803KShares$177 Million0.03% of portfolio
-
State Street Corp Boston, MA625KShares$138 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY430KShares$94.6 Million2.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI402KShares$88.4 Million0.17% of portfolio
Latest Institutional Activity in MDGL
Top Purchases
Top Sells
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Insider Transactions at MDGL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 14
2024
|
Fred B Craves |
SELL
Open market or private sale
|
Direct |
22,489
-0.53%
|
$4,835,135
$215.4 P/Share
|
|
May 14
2024
|
Fred B Craves |
BUY
Exercise of conversion of derivative security
|
Direct |
22,489
+2.55%
|
$2,293,878
$102.76 P/Share
|
|
Apr 08
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
26,270
-1.87%
|
$6,436,150
$245.85 P/Share
|
|
Apr 08
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
26,270
+11.03%
|
$236,430
$9.45 P/Share
|
|
Apr 08
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
2,676
-0.1%
|
$658,296
$246.17 P/Share
|
|
Apr 08
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,676
+0.58%
|
$24,084
$9.45 P/Share
|
|
Apr 05
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
27,613
-1.95%
|
$6,709,959
$243.19 P/Share
|
|
Apr 05
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
27,613
+11.46%
|
$248,517
$9.45 P/Share
|
|
Apr 05
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
27,506
-0.96%
|
$6,656,452
$242.86 P/Share
|
|
Apr 05
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,506
+5.35%
|
$247,554
$9.45 P/Share
|
|
Apr 04
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
18,710
-1.19%
|
$4,565,240
$244.68 P/Share
|
|
Apr 04
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
18,710
+8.38%
|
$168,390
$9.45 P/Share
|
|
Apr 04
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
18,537
-0.49%
|
$4,523,028
$244.5 P/Share
|
|
Apr 04
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,537
+3.74%
|
$166,833
$9.45 P/Share
|
|
Apr 03
2024
|
Paul A Friedman |
SELL
Open market or private sale
|
Direct |
27,407
-2.66%
|
$6,687,308
$244.37 P/Share
|
|
Apr 03
2024
|
Paul A Friedman |
BUY
Exercise of conversion of derivative security
|
Direct |
27,407
+11.39%
|
$246,663
$9.45 P/Share
|
|
Apr 03
2024
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
27,845
-1.16%
|
$6,794,180
$244.4 P/Share
|
|
Apr 03
2024
|
Rebecca Taub Pres., R&D, and CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
27,845
+5.41%
|
$250,605
$9.45 P/Share
|
|
Apr 02
2024
|
James M Daly Director |
SELL
Open market or private sale
|
Direct |
10,912
-27.97%
|
$2,673,440
$245.69 P/Share
|
|
Apr 02
2024
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,912
+47.4%
|
$1,145,760
$105.08 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 104K shares |
|---|---|
| Open market or private purchase | 425K shares |
| Exercise of conversion of derivative security | 293K shares |
| Open market or private sale | 293K shares |
|---|---|
| Payment of exercise price or tax liability | 4.11K shares |
| Other acquisition or disposition | 1.56M shares |